The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
March 11, 2021
View Complete Issue         Table of Contents 2019 
Lanadelumab (Takhzyro) for Prevention of Hereditary Angioedema (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lanadelumab (Takhzyro) for Prevention of Hereditary Angioedema (online only)
March 11, 2021 (Issue: 1619)
The FDA has approved lanadelumab-flyo (Takhzyro – Takeda), a subcutaneously-administered plasma kallikrein inhibitor, for prevention of hereditary angioedema (HAE) attacks in adults and children ≥12 years old. Lanadelumab is the third drug...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lanadelumab (Takhzyro) for Prevention of Hereditary Angioedema (online only)
Article code: 1619f
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.